FDA Rejects MDMA For PTSD Treatment, Calls For More Research On Psychedelic Therapy
The Food and Drug Administration (FDA) this week declined to approve the use of MDMA — popularly known as Ecstasy or Molly — for MDMA-assisted therapy for treating PTSD, disappointing many Americans who suffer with intractable mental health conditions and had pinned their hopes on the treatment.
There are only two FDA-approved treatments for PTSD, and MDMA would be the first to come on the market in decades. Friday’s decision comes at a time when there is growing interest in the use of alternative drugs to treat various mental health conditions, including depression and anxiety.
Though MDMA has long been associated with recreational use, its potential therapeutic benefits have garnered significant attention in recent years. Before its prohibition in 1985, MDMA was frequently used by psychotherapists to aid patients in addressing profound trauma.
Read Also: Five …